Development of a plasma biomarker panel for gastric cancer detection based on an autoimmune response signature.

Authors

null

Rongzhang Dou

MD Anderson Cancer Center, Houston, TX

Rongzhang Dou , Ehsan Irajizad , Yining Cai , Johannes Fahrmann , Jody Vykoukal , Hiroyuki Katayama , Yihui Chen , Ali Hussein Abdel Sater , Melissa Pizzi , Edwin J. Ostrin , Kohei Yamashita , Jaffer A. Ajani , Samir M Hanash

Organizations

MD Anderson Cancer Center, Houston, TX, University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Texas at MD Anderson Cancer Center, Houston, TX, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Funding

No funding received
None.

Background: Gastric cancer is frequently diagnosed at an advanced stage and is associated with poor outcomes. A humoral immune response to tumor antigens in the form of autoantibodies occurs early during tumor development. Harnessing autoantibodies and corresponding antigens has potential for diagnostic and therapeutics applications. Methods: Plasma samples from gastric cancer patients were collected before treatment and from non-gastric cancer cases and healthy controls for identification and quantitative analysis of immunoglobin (Ig)-bound antigens using mass spectrometry. The Ig-bound antigens were pulled down with a Protein A/G column for analysis by mass spectrometry. A protein A/G plate capture enzyme-linked immunosorbent assay (ELISA) was developed to validate Ig-bound MS results. A combined biomarker panel was established based on a logistic-regression model and ROC analysis was used to assess panel performance. Results: From a total of 983 proteins identified from gastric cancer samples, four Ig bound proteins were found to be enriched in gastric cancer plasmas compared with healthy controls and plasmas from other cancer types which yielded an area under the curve (AUC) of 0.973 (95% confidential interval [CI] = 0.92-1.00) for gastric cancer discrimination with a sensitivity of 0.91 at 95% specificity. Enzyme-linked immunosorbent assay (ELISA) based data yielded a high correlation (r = 0.72, P = 0.0199) with Ig-bound mass spectrometry data. These four proteins were found to be highly expressed in gastric cancer based on TCGA transcriptomic data with concordant tumor cell proteomic data. Conclusions: Our data reveal a panel of plasma Ig-bound antigens associated with the development of gastric cancer with potential application for gastric cancer detection and monitoring and potential therapeutic relevance.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Local-Regional Disease

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e16101)

DOI

10.1200/JCO.2023.41.16_suppl.e16101

Abstract #

e16101

Abstract Disclosures

Similar Abstracts